PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal ...
New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif., May 29, 2024 /PRNewswire/ -- 10x ...
PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer ...
The 10X Genomics Xenium Analyzer will support true single cell spatial transcriptomics on fresh frozen or fixed tissue samples. You can characterize 100s to 1000s of RNAs in cells and tissues using ...
After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...
PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a new non-peer-reviewed study has independently ...
On 4 February 2026, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer samples into high-resolution, multimodal datasets, backed by £18.9 million in ...
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. 10x Genomics is collaborating with PharosAI and leading UK institutions to build ...
Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (TXG) (Nasdaq: TXG), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results